Literature DB >> 8287599

T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour-infiltrating lymphocytes (TIL) from melanoma patients.

F Pandolfi1, L A Boyle, L Trentin, A Oliva, J T Kurnick.   

Abstract

The lymphocytes which infiltrate tumours and are grown in vitro to be used in adoptive immunotherapy are often characterized by dominant rearrangement of their T cell receptor (TCR) genes. To investigate the frequency and function of cells contributing to the 'dominant' rearrangement, we have cloned two bulk cell lines of TIL derived from melanoma patients (TIL-1 and TIL-5). These IL-2-propagated TIL cell lines had a CD8+ phenotype and exerted strong cytotoxic activity against autologous melanoma cells, but not against the natural killer (NK)-sensitive K-562 cell line or LAK targets such as Daudi cells. We derived 40 clones from TIL-1 and 23 from TIL-5. All tested clones were CD3+, CD4-, CD8+ and expressed the alpha/beta TCR. From TIL-1, 27 of 40 clones, and 13/19 of the TIL-5 clones lysed autologous tumour cells. In contrast to the NK-negative bulk cultures, K-562 killing was detected in 21 of the TIL-1 clones and 17 of the TIL-5 clones. TIL-1 contained eight clones and TIL-5 two clones with lytic capacity against neither autologous tumour cells nor the K562 cell line, although these clones possessed lytic potential as evidenced in a lectin-mediated lysis assay. LAK activity was not detected in most clones. Cytotoxic activity against autologous tumour could be inhibited by preincubation with anti-CD3 or anti-HLA class I MoAbs. Of the 34 TIL-1 clones analysed, 15 shared a rearranged TCR beta EcoRI restriction fragment of approximately 9.5 kb with the bulk culture. Clones sharing the EcoRI 10.5-kb dominant band present in TIL-5 bulk culture were also isolated. When the pattern of TCR beta rearrangement was compared with the cytotoxic functions, the following conclusions could be drawn: (i) clones contributing to the dominant band had heterogeneous functions. Most killed autologous tumour cells, but clones with no cytotoxic activity or even with no proliferative capacity in response to autologous tumour cells were also detected among those contributing rearrangement; (ii) some clones that share an apparently identical rearranged band different from the 'dominant' rearrangement, may demonstrate the same cytotoxic function. In addition, our data suggest that many of the clones that share the dominant rearrangement originated from diverse progenitors. The high frequency of clonally diverse anti-tumour reactive TIL is likely to be a reflection of the in vivo selection of the TCR repertoire at the site of tumour.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8287599      PMCID: PMC1534645          DOI: 10.1111/j.1365-2249.1994.tb06028.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2.

Authors:  R D Salter; R J Benjamin; P K Wesley; S E Buxton; T P Garrett; C Clayberger; A M Krensky; A M Norment; D R Littman; P Parham
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

2.  The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

Authors:  T L Darrow; C L Slingluff; H F Seigler
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

3.  Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.

Authors:  N J Crowley; C L Slingluff; T L Darrow; H F Seigler
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

4.  Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma.

Authors:  T Nitta; J R Oksenberg; N A Rao; L Steinman
Journal:  Science       Date:  1990-08-10       Impact factor: 47.728

5.  Induction by interleukin-2 of oligoclonal expansion of cultured tumor-infiltrating lymphocytes.

Authors:  A J Fishleder; J H Finke; R Tubbs; R M Bukowski
Journal:  J Natl Cancer Inst       Date:  1990-01-17       Impact factor: 13.506

6.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

7.  Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.

Authors:  R L Kradin; J T Kurnick; D S Lazarus; F I Preffer; S M Dubinett; C E Pinto; J Gifford; E Davidson; B Grove; R J Callahan
Journal:  Lancet       Date:  1989-03-18       Impact factor: 79.321

8.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

9.  Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.

Authors:  A Belldegrun; A Kasid; M Uppenkamp; S L Topalian; S A Rosenberg
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

10.  Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.

Authors:  N Gervois; F Heuze; E Diez; F Jotereau
Journal:  Eur J Immunol       Date:  1990-04       Impact factor: 5.532

View more
  3 in total

1.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.

Authors:  M Hishii; D Andrews; L A Boyle; J T Wong; F Pandolfi; P J van den Elsen; J T Kurnick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.

Authors:  M Hishii; J T Kurnick; T Ramirez-Montagut; F Pandolfi
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

3.  Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.

Authors:  T Ramirez-Montagut; D M Andrews; A Ihara; S Pervaiz; F Pandolfi; P J Van Den Elsen; R Waitkus; L A Boyle; M Hishii; J T Kurnick
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.